Miruvor
Sign up
The short answer

What studies of Ozone therapy and EBOO found

12papers on Ozone therapy and EBOO
499people in 7 studies testing Ozone therapy and EBOO alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the randomised trial and studies with no comparison group (very low certainty): 11 findings, all C.

9 outcomes rated · see each below

ME/CFS: C Might help, very uncertain

Based on the strongest evidence, studies with no comparison group (very low certainty): 2 findings, all C.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, Ozone therapy and EBOO might help some people, but research can’t show it yet. For ME/CFS, Ozone therapy and EBOO might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 12 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Ozone therapy and EBOO · Long COVID is hereOzone therapy and EBOO · ME/CFS is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Fatigue2 studies · 140 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group2 studies · 140 people with results

Fatigue improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on fatigue in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
  1. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. (2026)

    People in the study
    45 in the study · 40 with outcome data
    Dose
    20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions
    Outcome
    FACIT Fatigue Scale Functional assessment of chronic illness treatment
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy - preliminary results on 100 patients. (2021)

    People in the study
    100 in the study
    Dose
    "40-50 mg/150-200 ml ozone into 150/200 ml blood", "usually 2-3 O2-O3AHT (major) treatments each week for 2–3 weeks"
    Outcome
    PASC symptoms, i.e., fatigue Fatigue Severity Scale
    Effect
    better
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Anxiety1 study · 40 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (40 in all).

Studies with no comparison group45 in the study · 40 with outcome data · 10 sessions · 20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions

Anxiety improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on anxiety in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (40 in all)
See the 1 study
  1. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. (2026)

    People in the study
    45 in the study · 40 with outcome data
    Dose
    20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions
    Outcome
    Beck Anxiety Inventory
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 40 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (40 in all).

Studies with no comparison group45 in the study · 40 with outcome data · 10 sessions · 20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions

Depression improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on depression in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (40 in all)
See the 1 study
  1. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. (2026)

    People in the study
    45 in the study · 40 with outcome data
    Dose
    20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions
    Outcome
    Beck Depression Inventory
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 40 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (40 in all).

Studies with no comparison group45 in the study · 40 with outcome data · 10 sessions · 20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions

Pain improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (40 in all)
See the 1 study
  1. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. (2026)

    People in the study
    45 in the study · 40 with outcome data
    Dose
    20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions
    Outcome
    pain Short Form-36
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 40 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (40 in all).

Studies with no comparison group45 in the study · 40 with outcome data · 10 sessions · 20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions

Sleep improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (40 in all)
See the 1 study
  1. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. (2026)

    People in the study
    45 in the study · 40 with outcome data
    Dose
    20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions
    Outcome
    global Pittsburgh Sleep Quality Index Pittsburgh Sleep Quality Index
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study · 35 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all).

The randomised trial73 randomised

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of ozone therapy and EBOO on breathlessness in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)
See the 1 study
  1. A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19. (2024)

    People in the study
    73 randomised
    Dose
    —
    Outcome
    tidal volume
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Daily life and health overall

Overall symptoms2 studies · 135 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all).

The randomised trial73 randomised

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of ozone therapy and EBOO on overall symptoms in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)

Studies with no comparison group100 in the study · at least one week later · "40-50 mg/150-200 ml ozone into 150/200 ml blood", "usually 2-3 O2-O3AHT (major) treatments each week for 2–3 weeks"

Overall symptoms improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19. (2024)

    People in the study
    73 randomised
    Dose
    —
    Outcome
    intervention effectiveness
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    Low
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy - preliminary results on 100 patients. (2021)

    People in the study
    100 in the study
    Dose
    "40-50 mg/150-200 ml ozone into 150/200 ml blood", "usually 2-3 O2-O3AHT (major) treatments each week for 2–3 weeks"
    Outcome
    health status amelioration
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life2 studies · 63 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).

Studies with no comparison group2 studies · 63 people with results

Quality of life improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on quality of life in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
  1. Ozone therapy by rectal insufflation in long COVID syndrome: a preliminary study with thermographic evaluation and quality of life measurement. (2026)

    People in the study
    23 in the study
    Dose
    8 mg of medical ozone (200 mL of gas at a concentration of 40 µg/mL) was administered per session, Five sessions per week were administered during the first two weeks, two sessions per week from weeks 3 to 6, and one session per week from weeks 7 to 12
    Outcome
    Physical Component Summary (PCS) Short-Form Health Survey (SF-12)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome. (2026)

    People in the study
    45 in the study · 40 with outcome data
    Dose
    20 μg/mL first session, 25 μg/mL second session, 30 μg/mL third to tenth sessions; 100 mL blood and 100 mL O₃-O₂ mixture gas, 2–3 times per week, totaling 10 sessions
    Outcome
    physical functioning Short Form-36
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning2 studies · 58 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (73 in all).

The randomised trial73 randomised

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of ozone therapy and EBOO on daily functioning in long COVID. Improvement · very low certainty C

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • Few people (73 in all)

Studies with no comparison group23 in the study · 12 weeks · 8 mg of medical ozone (200 mL of gas at a concentration of 40 µg/mL) was administered per session, Five sessions per week were administered during the first two weeks, two sessions per week from weeks 3 to 6, and one session per week from weeks 7 to 12

Daily functioning improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (23 in all)
See the 2 studies
  1. A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19. (2024)

    People in the study
    73 randomised
    Dose
    —
    Outcome
    predicted 6MWD 6-minute walk distance
    Effect
    better
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    High
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns
  2. Ozone therapy by rectal insufflation in long COVID syndrome: a preliminary study with thermographic evaluation and quality of life measurement. (2026)

    People in the study
    23 in the study
    Dose
    8 mg of medical ozone (200 mL of gas at a concentration of 40 µg/mL) was administered per session, Five sessions per week were administered during the first two weeks, two sessions per week from weeks 3 to 6, and one session per week from weeks 7 to 12
    Outcome
    grip strength test Handgrip Strength Test (HST)
    Effect
    better
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

ME/CFS

Symptoms

Fatigue1 study · 200 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group224 in the study · 200 started · not less than two weekly sessions · 45 μg/mL of ozone in a O2-O3 mixture, not less than two weekly sessions

Fatigue improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on fatigue in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 1 study
  1. Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy. (2021)

    People in the study
    224 in the study · 200 started
    Dose
    45 μg/mL of ozone in a O2-O3 mixture, not less than two weekly sessions
    Outcome
    significant ameliorations of fatigue, of 4–6 delta score Fatigue Severity Scale
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms2 studies · 101 people received Ozone therapy and EBOO Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.

Studies with no comparison group2 studies · 101 people with results

Overall symptoms improved.

The evidence is very uncertain about the effect of ozone therapy and EBOO on overall symptoms in ME/CFS. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Not all results were tested against chance
See the 2 studies
  1. Oxygen-Ozone Therapy is an Effective Therapy in Chronic Fatigue Syndrome: Results in 100 Patients (2019)

    People in the study
    100 in the study
    Dose
    two times a week for one month and then, twice a month as maintenance therapy
    Outcome
    significant improvement in symptomatology (>50% improvement in symptoms)
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
  2. Oxygen-ozone therapy in meningoencephalitis and chronic fatigue syndrome. Treatment in the field of competitive sports: case report (2019)

    People in the study
    1 in the study
    Dose
    150 cc at a concentration of 35 mcg, bi-weekly intervals for 4 weeks, continued treatment on a weekly basis for a further 4 weeks
    Outcome
    complete remission of the symptoms of asthenic, neurological and clinical parameters
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    8 to 40 mg at the start

  2. 2Raise

    Raised step by step in 1 of 2 studies

  3. 3Top dose

    Most often 8 mg (1 of 2 studies)

Doses across 2 studies

8 to 50 mg.

Each study’s dose, as printed

All papers

  1. A pilot randomized controlled trial of major ozone autohemotherapy for patients with post-acute sequelae of COVID-19.2024 · randomised trial · 73 randomised
    Summary

    This preprint abstract reports a prospective randomised controlled trial of major ozone autohemotherapy (O 3 -MAH) plus conventional therapy versus conventional therapy alone in 73 people with post-acute sequelae of COVID-19 (PASC). Participants were assigned to O 3 -MAH plus conventional therapy (n=35) or conventional therapy alone (n=38). The abstract does not state where participants were recruited, the dose, route or schedule of O 3 -MAH, or how long treatment lasted. Symptom score, pulmonary function, 6-minute walk distance (6MWD), and hematological, biochemical and immunological parameters were assessed before and after intervention. Both groups improved, but the abstract reports greater improvement in the O 3 -MAH group. With response defined as a ≥50% reduction in symptom score, 25 of 35 patients (71%) responded to O 3 -MAH and 17/38 patients (45%) responded to conventional treatment alone (P=0.0325). The abstract reports significant improvements in symptom scores (P=0.0478), tidal volume (P=0.0374), predicted 6MWD (P=0.0032), and coagulation and inflammatory indicators in the O 3 -MAH group compared with the conventional treatment group. It also states that cellular immunity improved and that this improvement became more pronounced with extended treatment duration. The abstract does not report side effects or withdrawals. The authors state that further research is needed to validate the findings and establish longer-term benefits.

  2. Male vs. Female Differences in Responding to Oxygen-Ozone Autohemotherapy (O2-O3-AHT) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).2021 · compared with another group · 224 in the study · 200 started
    Summary

    This study asked whether male and female patients with ME/CFS differ in their response to oxygen–ozone autohemotherapy (O2-O3-AHT). In total, 224 outpatients from clinical centers in Pordenone and Gorle (Bergamo) were enrolled; 200 entered the study, comprising 69 men (34.5%) and 131 women. Patients received O2-O3-AHT with 45 μg/mL of an O3 mixture in O2 via autohemotherapy, with no fewer than two weekly sessions, and were followed up after 30 days following the second O2-O3-AHT session. Fatigue was measured with the Fatigue Severity Scale (FSS), a 7-point scoring system, before and after treatment. The paper reports that female patients showed a better outcome than males: the average FSS score was 5.14 ± 1.18 SD for females and 4.03 ± 1.80 SD for males (p = 0.0001). In the youngest age cohort (14–29 years), the paper reports p = 0.006 for the Δ = 28.3% (males = 3.8, females = 5.3). The male age clusters lacked statistical significance (p = 0.76). The paper also states no difference in FSS score across three age clusters for either females or males. Before the study, 19 were excluded and five never started. Harms were not reported.

  3. Ozone therapy by rectal insufflation in long COVID syndrome: a preliminary study with thermographic evaluation and quality of life measurement.2026 · no comparison group · 23 in the study
    Summary

    This preliminary open-label study examined rectal ozone insufflation in 23 patients with post-acute COVID-19 syndrome (long COVID) from the Long-Covid Association of Murcia. All 23 were recruited and finished the study. Participants received medical ozone by rectal insufflation, 8 mg per session (200 mL of gas at 40 µg/mL), over a 12-week period, with assessments at baseline (T0), after 6 weeks (T1), and after 12 weeks (T2). There was no control group. Outcomes were handgrip strength, quality of life on the SF-12 physical (PCS) and mental (MCS) component summaries, and abdominal skin temperature by infrared thermography. Handgrip strength improved from T0 to T1 (p = 0.0003) but not from T1 to T2 (p = 0.957). PCS improved from T0 to T1 (p = 0.0038) but not from T1 to T2 (p = 0.5933). MCS improved from T0 to T1 (p = 0.0088) but not from T1 to T2 (p = 0.3917). Temperature changed from T0 to T1 (p = 0.0465) but not from T1 to T2 (p = 0.1038). No significant differences between the sexes were observed for any of the four parameters. The authors reported no adverse events of interest recorded. They state the open-label design lacked a control group and placebo effects cannot be ruled out.

  4. Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome.2026 · no comparison group · 45 in the study · 40 with outcome data
    Summary

    This retrospective medical records review study examined major ozone autohemotherapy (MBO) in patients diagnosed with post-COVID syndrome at Başkent University Alanya Hospital outpatient clinic. A total of 45 patients were enrolled; due to missing data, five patients were excluded, and a total of 40 patients were evaluated. Patients attended and agreed to 10 sessions of MBO, administered 2–3 times per week. The first session used 20 μg/mL, the second 25 μg/mL, and the third to tenth sessions 30 μg/mL; 100 mL of blood was collected and 100 mL of O₃-O₂ mixture gas was injected, then the ozonated blood was reinfused intravenously. There was no comparison group; scores before and after the 10 sessions were compared. Measures were the FACIT Fatigue Scale, Beck Depression Inventory, Beck Anxiety Inventory, Pittsburgh Sleep Quality Index, and Short Form-36. Significant improvements were reported in FACIT scores (p = 0.001), Beck Depression Inventory (p = 0.002), Beck Anxiety Inventory (p = 0.001), and global Pittsburgh Sleep Quality Index (p = 0.016). Sleep latency (p = 0.059), sleep efficiency (p = 1.000), and use of sleep medication (p = 0.066) showed no significant change; emotional well-being on Short Form-36 also showed no significant change (p = 0.394). Harms were not reported. The authors state the small sample size and lack of prospective studies and a control group as limitations.

  5. Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy.2021 · no comparison group · 224 in the study · 200 started
    Summary

    This study asked whether oxygen-ozone autohemotherapy (O2-O3-AHT) improves fatigue in patients with ME/CFS. It recruited 224 outpatients at clinical centers in Pordenone and Gorle (Bergamo); 200 entered the study, 19 did not follow up and were excluded, and 5 accepted but never started. There was no comparison group and no randomisation or crossover; outcomes were within-person before-and-after measures. Patients underwent not less than two weekly sessions of major O2-O3-AHT, with 200 mL blood treated with 45 μg/mL of ozone in an O2-O3 mixture and reintroduced; follow-up was at 30 days after the second session. Fatigue was measured with a 7-scoring Fatigue Severity Scale before and following 30 days after treatment. The authors report that 43.5% evolved from worst score 7 to best score 1; 77.5% had significant ameliorations of fatigue of 4–6 delta score; higher than 75% had a delta scoring of 4–6 points; 5% reported very small, quite negligible improvements; 51% responded with maximal FSS delta score; and 59.48% of males versus 74.58% of females responded. No patient showed side effects, and no patient reported adverse manifestation over the next 3 months. The authors state that further insights are needed to elucidate mechanisms, and that mechanisms remain far from fully elucidated.

  6. Oxygen-Ozone Therapy is an Effective Therapy in Chronic Fatigue Syndrome: Results in 100 Patients2019 · no comparison group · 100 in the study
    Summary

    This single-group report describes oxygen-ozone therapy in chronic fatigue syndrome (CFS). At the Tirelli Medical Clinic, Pordenone, Italy, from February 2016 to December 2018, the authors state they treated 100 patients with auto hemo-transfusion (GAE) according to SIOOT protocols, two times a week for one month and then twice a month as maintenance therapy. The report describes a single treated group ('Among the 100 patients with CFS treated'), with no separate comparison group reported. Randomisation, blinding, and allocation details are not reported. Fatigue was evaluated with the Fatigue Severity Scale. Among the 100 patients with CFS treated, 70 patients (70%) developed a significant improvement in symptomatology (>50% improvement in symptoms). No side effects to ozone therapy have been reported. Withdrawals for harms and the observation period are not reported. The authors conclude that oxygen ozone therapy is an effective therapy in the treatment of CFS; they do not state limitations.

  7. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy - preliminary results on 100 patients.2021 · case report · 100 in the study
    Summary

    This clinical multicenter case series enrolled 100 Caucasian outpatients with post-acute sequelae of SARS-CoV2 (PASC) and fatigue after previous COVID-19; patients were examined at clinics in Pordenone and Bergamo. All received oxygen-ozone autohemotherapy (O2-O3-AHT) by major auto-hemotransfusion, usually 2-3 treatments each week for 2–3 weeks, with 40-50 mg/150-200 ml ozone into 150/200 ml blood; some had at least one treatment. There was no comparison group. Fatigue was measured with the Fatigue Severity Scale before treatment and at least one week after treatment. The report states that O2-O3-AHT reduced PASC symptoms, i.e. fatigue, by at least 67% as a mean in the whole cohort (H = 148.4786, p < 0.0001). It reports that about two fifths (around 40%) quite completely recovered for PASC-associated fatigue, that the highest FSS delta (ΔFSS = - 6) was 36%, the lowest (ΔFSS = - 1) 3%, and ΔFSS = - 2 9%; 85% reported FSS amelioration from 7 to at least 3. The effect was reported as not influenced by sex distribution (H = 0.7353, p = 0.39117). All treated patients except three with very modest changes strongly ameliorated their health status. Harms and withdrawals were not reported. The authors state limitations including pre-clinical data, confounders and cohort size.

  8. Oxygen-ozone therapy in meningoencephalitis and chronic fatigue syndrome. Treatment in the field of competitive sports: case report2019 · case report · 1 in the study
    Summary

    This was a case report of one patient, a 14-year-old boy who arrived in the Emergency Room of the authors' hospital for persistent hyperpyrexia, headache and prolonged emetic episodes and complaining of objective photophobia and dizziness. He was diagnosed with post-infectious chronic fatigue syndrome after meningoencephalitis. The patient was treated with oxygen-ozone therapy by rectal insufflation, 150 cc at a concentration of 35 mcg, at bi-weekly intervals for 4 weeks, continued weekly for a further 4 weeks, associated with Micetrin at double daily dosage for the first two weeks followed by single daily dosage for the entire treatment period. There was no comparison group. Outcomes concerned symptom remission and neurological examination. The report states complete remission of the symptoms of asthenic, neurological and clinical parameters, and complete remission of asthenic symptoms and regression of cephalic, vertiginous and myalgic symptoms. Two months after discharge, the Neurological Objective Examination was within normal limits with a slightly positive Romberg and some uncertainty in digital dexterity tests associated with nuanced bilateral tremor. Harms, worsening and withdrawals were not reported. The authors state no limitations.

  9. Assessment and management of post-COVID-19 pulmonary complications: a rapid review.2026 · review
    Summary

    This rapid review assessed evidence on management and treatment of pulmonary complications in post-COVID-19 condition (PCC). It included 73 unique records from published and grey literature; these comprised guidance documents, secondary studies and primary research studies. Included primary studies involved adults with PCC and pulmonary complications, with individual study sizes that included 28 and 871 participants. Interventions included IHHT plus standard rehabilitation, nirmatrelvir plus ritonavir, hyperbaric oxygen, systemic corticosteroids, and multicomponent exercise rehabilitation. Comparisons included standard rehabilitation, placebo plus ritonavir, sham treatment, nonsteroid care, and usual care or control. Outcomes included 6MWT distance, Borg and PROMIS dyspnoea, RAND-36 physical function, FEV1, FVC, FVC % pred, resting oxygen requirement and adverse events. Doehner 2024 reported a significant between-group difference in 6MWT distance favouring IHHT plus rehabilitation (p<0.001). Geng 2024 found no between-group difference in PROMIS dyspnoea (p>0.05). Kjellberg 2025 found no difference in RAND-36 physical function (p=0.277) or 6MWT distance (p=0.62) with hyperbaric oxygen versus sham. Ntiamoah 2024 reported significant improvements in FEV1, FVC and FVC % pred in the steroid group only. Torres 2024 reported FVC % pred improved from 52±0.17% to 60±0.20% (p=0.019) and resting oxygen requirement reduced (p=0.005), with no significant change in 6MWT distance (p=0.50). Seo 2025 reported diarrhoea in 80% of patients with nintedanib; Ora 2023 reported no adverse events with sodium pyruvate nasal spray. The authors state study quality and risk of bias were heterogeneous and findings should be interpreted with caution.

  10. Medical Ozone in Rheumatology: From Redox Modulation to Clinical Applications in Autoimmune and Degenerative Diseases—A Narrative Review2025 · review
    Summary

    This narrative review examined medical ozone therapy across rheumatologic conditions, including ME/CFS, drawing on a structured search of PubMed and Scopus from January 2000 to October 2025; the paper is a preprint marked NOT PEER-REVIEWED. The author reports no study of his own and no randomised or placebo-controlled comparison of ozone in ME/CFS; instead the review describes observational studies it cites. For ME/CFS it describes an open-label study involving 65 patients with chronic fatigue syndrome in which oxygen–ozone autohemotherapy was associated with marked reductions in fatigue severity without serious adverse effects; a larger cohort of 100 patients in which approximately 70% achieved at least a 50% improvement in fatigue symptoms following ozone therapy; and a multicentre observational study including 200 patients with ME/CFS reporting substantial improvements on the Fatigue Severity Scale, with a significant proportion shifting from the highest to the lowest fatigue scores, more than three-quarters of patients experiencing clinically meaningful reductions in fatigue, and treatment well tolerated across age and sex groups. No numbers for withdrawals, dropouts or the number of included studies were reported. The author states that placebo effects cannot be excluded and that the evidence is derived largely from uncontrolled studies.

  11. Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
    Summary

    This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.

  12. The Mito-Hormetic Mechanisms of Ozone in the Clearance of SARS-CoV2 and in the COVID-19 Therapy.2022 · review
    Summary

    This narrative review aims to describe molecular mechanisms of medical ozone, summarize clinical evidence for O2–O3 therapy in COVID-19, and discuss its potential in PASC. It reports no own cohort: enrolled, started, and analysed numbers are not reported, there is no comparison group, and it is not randomised or crossover. The review cites a report in which O2–O3 therapy was administered to 200 ME/CFS patients; significant improvements in the fatigue rate were described in 77.5% of patients, with half reporting total resolution of symptoms 30 days after treatment. It also states that the same results were reproduced in a cohort of 100 PASC patients for chronic fatigue and systemic pain, and that females were more responsive than men. For harms, the review states improper ozone administration protocols may also induce encephalopathy and central nervous system toxicity. The authors conclude that despite positive preliminary results, more evidence is needed to assess the feasibility, safety, and efficacy of O2–O3 therapy in the context of PASC. No numerical side-effect counts, withdrawals, or between-group results are reported for this review.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime